Crescita Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	22.07	19.58	17.52	23.53	16.77	15.64
Revenue Growth (YoY)	26.79%	11.74%	-25.52%	40.29%	7.22%	-29.98%
Cost of Revenue	10.64	9.97	7.16	10.34	6.76	4.37
Gross Profit	11.42	9.61	10.36	13.18	10.01	11.27
Selling, General & Admin	10.18	10.68	10.12	10.57	9.5	7.85
Research & Development	0.57	0.65	0.7	0.61	0.63	1.1
Operating Expenses	12.2	12.7	12.32	12.65	11.51	10.44
Operating Income	-0.78	-3.09	-1.96	0.53	-1.5	0.83
Interest Expense	-0.05	-0.07	-0.09	-0.16	-0.24	-0.25
Interest & Investment Income	0.4	0.5	0.51	0.26	0.18	0.29
Earnings From Equity Investments	-0.07	-0.05	0.02	-0.06	0.01	-
Currency Exchange Gain (Loss)	0.14	-0.04	0.01	-0.05	-0.24	0.18
Other Non Operating Income (Expenses)	1.1	-	-	-	-	-
EBT Excluding Unusual Items	0.74	-2.75	-1.51	0.52	-1.79	1.05
Merger & Restructuring Charges	-0.13	-0.13	-	-	-	-
Asset Writedown	-	-	-	-	-	-1.92
Other Unusual Items	0.11	0.11	-0.02	-0.12	0.78	1.39
Pretax Income	0.44	-2.76	-1.53	0.4	-1.01	0.52
Income Tax Expense	-0.01	-0.01	0.46	-0.46	0.1	0.48
Earnings From Continuing Operations	0.46	-2.75	-1.99	0.86	-1.11	0.04
Net Income	0.46	-2.75	-1.99	0.86	-1.11	0.04
Net Income to Common	0.46	-2.75	-1.99	0.86	-1.11	0.04
Net Income Growth	-	-	-	-	-	-98.00%
Shares Outstanding (Basic)	19	19	20	21	21	21
Shares Outstanding (Diluted)	19	19	20	21	21	21
Shares Change (YoY)	-2.70%	-4.44%	-3.55%	1.18%	-1.02%	-6.79%
EPS (Basic)	0.02	-0.14	-0.10	0.04	-0.05	0.00
EPS (Diluted)	0.02	-0.14	-0.10	0.04	-0.05	0.00
EPS Growth	-	-	-	-	-	-97.96%
Free Cash Flow	0.62	0.63	1.94	-1.25	-1.94	5.55
Free Cash Flow Per Share	0.03	0.03	0.10	-0.06	-0.09	0.27
Gross Margin	51.77%	49.07%	59.15%	56.03%	59.72%	72.08%
Operating Margin	-3.54%	-15.77%	-11.16%	2.25%	-8.92%	5.33%
Profit Margin	2.07%	-14.04%	-11.33%	3.66%	-6.59%	0.24%
Free Cash Flow Margin	2.82%	3.21%	11.09%	-5.31%	-11.59%	35.48%
EBITDA	0.25	-2.15	-0.86	1.61	-0.48	2.02
EBITDA Margin	1.13%	-10.96%	-4.89%	6.86%	-2.86%	12.91%
D&A For EBITDA	1.03	0.94	1.1	1.08	1.02	1.19
EBIT	-0.78	-3.09	-1.96	0.53	-1.5	0.83
EBIT Margin	-3.54%	-15.77%	-11.16%	2.25%	-8.92%	5.33%
Effective Tax Rate	-	-	-	-	-	92.88%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.